Tr1X: Inducing long-term immune tolerance with allogeneic Tr1 cells

As B cell-depleting CAR Ts are shifting the autoimmune disease goalposts from management to durable remission, Tr1X believes regulatory T cell biology could provide a route to long-lasting immune reset in indications less well-suited to CAR T approaches. The San Diego biotech is engineering off-the-shelf allogeneic type 1 regulatory T cells, or Tr1 cells, to induce immune tolerance in refractory I&I diseases.

Tr1X Inc.’s focus on Tr1 cells sets it apart from much of the Treg cell therapy field, where most programs are based on FOXP3-expressing Tregs. Tr1 cells are a distinct regulatory T cell subset whose suppressive identity is not defined by FOXP3 expression but by high IL-10 production and IL-10-dependent immune regulation...